ClinicalTrials.Veeva

Menu

A Study of Biomarkers of Mild Traumatic BRAIN Injury (BRAINI)

Grenoble Alpes University Hospital Center (CHU) logo

Grenoble Alpes University Hospital Center (CHU)

Status

Completed

Conditions

Mild Traumatic Brain Injury

Treatments

Other: 2 x 5 mL blood sample

Study type

Observational

Funder types

Other

Identifiers

NCT04032509
2019-A01525-52 (Other Identifier)
38RC19.176

Details and patient eligibility

About

Patients with mild traumatic brain injury (mTBI) represent a burden of patients admitted to the emergency department. According to the guidelines, a cerebral CT scan is indicated after mTBI according to the specific conditions. However, variability exists regarding the respect of these CT scan indications, and less than 10% of patients will have visible brain lesions on CT scan. Recently, serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) biomarkers have shown ability to differentiate normal and abnormal CT scan findings after mTBI. These encouraging results prompted us to launch a prospective study using automated and quick measurements of GFAP and UCH-L1 biomarkers to validate these findings.

Enrollment

1,501 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients >18 years old (France)

  • Mild TBI (GCS 13-15 on admission) within 12 hours after injury

  • Indication of brain CT scan:

    • neurological focal deficit
    • anterograde amnesia
    • Glasgow coma scale score <15 after 2 hours post-TBI
    • suspicion of vault depression fracture
    • fracture of the basal skull
    • persisting nausea, vomiting or headache
    • post-TBI seizures
    • Pre-injury treatment with antithrombotic drugs
    • Loss of consciousness or amnesia with age >65 years, fall >1m or hit pedestrian
    • Other condition requiring CT scan according to the in-charge physician.

Exclusion criteria

  • GCS 3-12 on admission
  • Time of injury unknown
  • Time to injury exceeding 12 hours
  • Primary admission for non-traumatic neurological disorder (e.g., stroke, spontaneous intracranial hematoma)
  • Penetrating head trauma
  • Patient with mechanical ventilation
  • Pre-injury neurological disorder affecting the assessment of neurological outcome: dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumor, and history of neurosurgery, stroke or transient ischemic attack (TIA) within the last 30 days
  • Venipuncture not feasible
  • No realization of brain CT-scan
  • Subject under judiciary control
  • Pregnant or breastfeeding woman
  • Subject in exclusion period of another study

Trial design

1,501 participants in 1 patient group

Mild TBI
Description:
Mild TBI (GCS 13-15 on admission) within 12 hours after injury
Treatment:
Other: 2 x 5 mL blood sample

Trial contacts and locations

16

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems